From anti-drug antibody incidence to clinical relevance: interpreting highly sensitive immunogenicity assays in biosimilars.
- DOI
- 10.1080/17576180.2026.2715917
- Published
- 2026-07-01
- Container
- Bioanalysis
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/17576180.2026.2715917,
title = {From anti-drug antibody incidence to clinical relevance: interpreting highly sensitive immunogenicity assays in biosimilars.},
author = {Krishnan A and Bp S and Mehta G and Ramaswamy S and Chakraborty S and Mandal S.},
year = {2026},
journal = {Bioanalysis},
doi = {10.1080/17576180.2026.2715917},
url = {https://doi.org/10.1080/17576180.2026.2715917}
}RIS
TY - JOUR TI - From anti-drug antibody incidence to clinical relevance: interpreting highly sensitive immunogenicity assays in biosimilars. AU - Krishnan A AU - Bp S AU - Mehta G AU - Ramaswamy S AU - Chakraborty S AU - Mandal S. PY - 2026 JO - Bioanalysis DO - 10.1080/17576180.2026.2715917 UR - https://doi.org/10.1080/17576180.2026.2715917 ER -
APA
A, K., S, B., G, M., S, R., S, C., & S., M. (2026). From anti-drug antibody incidence to clinical relevance: interpreting highly sensitive immunogenicity assays in biosimilars.. Bioanalysis. https://doi.org/10.1080/17576180.2026.2715917
Source records
- europe-pmc · retrieved 2026-09-26T00:57:19.260Z